World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   137 records for 32 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4
Recruitment statusMain ID Public TitleDate of Registration
RecruitingISRCTN91737921
ODYSSEY: Once daily Dolutegravir in Young people vS Standard thErapY
08/08/2014
AuthorisedEUCTR2013-000087-29-IT
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000087-29-FIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/07/2013
AuthorisedEUCTR2013-000087-29-SIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.03/09/2013
AuthorisedEUCTR2013-000087-29-LVInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.02/09/2013
AuthorisedEUCTR2013-000087-29-EEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.10/10/2013
AuthorisedEUCTR2013-000087-29-GRInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.21/10/2013
AuthorisedEUCTR2013-000087-29-ESInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.12/07/2013
AuthorisedEUCTR2013-000087-29-SEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.29/10/2013
AuthorisedEUCTR2013-000087-29-DEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.08/07/2013
AuthorisedEUCTR2013-000087-29-LTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.28/01/2014
AuthorisedEUCTR2013-000087-29-PLInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.04/11/2013
RecruitingNCT01905943A Safety Study of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia19/07/2013
AuthorisedEUCTR2013-000087-29-BEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.13/01/2014
02/07/2013
AuthorisedEUCTR2012-003138-17-AT
Clinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003138-17-PTClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer04/06/2013
AuthorisedEUCTR2012-003138-17-GRClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer25/06/2013
AuthorisedEUCTR2012-003138-17-LVClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer10/05/2013
Not RecruitingEUCTR2012-003138-17-FIClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer20/05/2013
AuthorisedEUCTR2012-003138-17-ESClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer16/05/2013
AuthorisedEUCTR2012-003138-17-ITClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer03/05/2013
AuthorisedEUCTR2012-003138-17-IEClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer03/05/2013
AuthorisedEUCTR2012-003138-17-BGA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/06/2013
RecruitingNCT01860638A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma21/05/2013
AuthorisedEUCTR2012-003138-17-GBA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
AuthorisedEUCTR2012-003138-17-SEClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer30/05/2013
AuthorisedEUCTR2012-003138-17-EEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
24/04/2013
Not recruitingNCT01825512
Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
03/04/2013
AuthorisedEUCTR2012-003647-30-GB
A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003647-30-ESA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).29/10/2012
AuthorisedEUCTR2012-003647-30-GRA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).14/11/2012
AuthorisedEUCTR2012-003647-30-DEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-LVA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-HUA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-ITA multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)11/01/2013
AuthorisedEUCTR2012-003647-30-PLA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).12/02/2013
AuthorisedEUCTR2012-003647-30-CZA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).28/11/2012
AuthorisedEUCTR2012-003647-30-ATA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).07/02/2013
AuthorisedEUCTR2012-003647-30-EEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).19/11/2012
AuthorisedEUCTR2012-003647-30-BGA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).10/05/2013
AuthorisedEUCTR2012-003647-30-SKA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).20/02/2014
23/10/2012
AuthorisedEUCTR2012-000353-31-IT
Efficacy and safety study to compare deferiprone versus deferasirox in paediatric patients
Recruitment statusMain IDPublic titleDate of registration
Not AvailableEUCTR2012-000353-31-Outside-EU/EEAEfficacy and safety study to compare deferiprone versus deferasirox in paediatric patients10/04/2013
11/10/2012
AuthorisedEUCTR2011-003669-14-ES
Tranexamic Acid for the treatment of significant traumatic head injury - CRASH-3
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2011-003669-14-GBTranexamic Acid for the treatment of significant traumatic head injury - CRASH-303/07/2012
RecruitingPACTR201210000441277Clinical Randomisation of an Antifibrinolytic in Significant Head Injury (CRASH-3)24/10/2012
12/06/2012
Not RecruitingCTRI/2012/05/002622
"Role of Tranexamic Acid (TXA) to reduce the bleeding in post delivery cases"
02-05-2012
Not RecruitingIRCT201012265467N1
The Impact of Omega-3 on Dry Eye
2012-04-03
Not RecruitingEUCTR2011-005550-57-LV
A clinical study in patients with multiple sclerosis to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml (experimental drug). 09/02/2012
    
1 2 3 4
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history